Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
APLM Stock Forecast 2026-2027
$19.90
Current Price
$42.44M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to APLM Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
APLM Price Momentum
-0.8%
1 Week Change
+0.6%
1 Month Change
+158.8%
1 Year Change
+6.5%
Year-to-Date Change
-52.8%
From 52W High of $42.12
+443.9%
From 52W Low of $3.66
📊 TOP ANALYST CALLS
Did APLM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Apollomics is one of their latest high-conviction picks.
Latest APLM Stock Price Targets & Analyst Predictions
APLM has shown a year-to-date change of 6.5% and a 1-year change of 158.8%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for APLM. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
APLM Analyst Ratings
0
Buy
0
Hold
0
Sell
APLM Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $19.90
Latest APLM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for APLM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $2.00 |
| Apr 1, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $5.00 |
| Apr 1, 2024 | EF Hutton | Michael King | Buy | Maintains | $6.50 |
| Nov 20, 2023 | HC Wainwright & Co. | Buy | Reiterates | $17.00 | |
| Oct 3, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $17.00 |
| Aug 23, 2023 | EF Hutton | Michael King | Buy | Assumes | $25.00 |
| Jun 5, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $18.00 |
| Jun 1, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Initiates | $18.00 |
| May 25, 2023 | EF Hutton | Michael King | Buy | Assumes | $25.00 |
| Apr 25, 2023 | EF Hutton | Michael King | Buy | Initiates | $25.00 |
Apolomics Inc. (APLM) Competitors
The following stocks are similar to Apollomics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Apolomics Inc. (APLM) Financial Data
Valuation Metrics
Market Cap
$42.44M
Enterprise Value
$20.49M
P/E Ratio
N/A
PEG Ratio
-30.6x
Price/Sales
6.2x
Growth & Margins
Revenue Growth (YoY)
+380.8%
Gross Margin
N/A
Operating Margin
-124.8%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+9.6%
Current Ratio
1.0x
Debt/Equity
0.2x
ROE
-380.1%
ROA
-72.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Apolomics Inc. (APLM) Business Model
About Apolomics Inc.
What They Do
Develops cell and gene therapies for cancer.
Business Model
Apolomics Inc. operates by innovating in the biopharmaceutical sector, specifically focusing on cell and gene therapies to treat cancer. The company generates revenue through the development of novel therapeutic solutions, particularly in immuno-oncology and oncogene targeting therapies, often collaborating with scientific institutions to enhance its research and development efforts.
Additional Information
Headquartered in the United States, Apolomics is dedicated to leveraging advanced biotechnology platforms to create precision medicine solutions tailored to specific malignancies. Its work not only aims to improve patient outcomes but also contributes to broader advancements in the healthcare industry, particularly in oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
13
CEO
Mr. Hung-Wen Chen
Country
United States
IPO Year
2021
Website
www.apollomicsinc.comApolomics Inc. (APLM) Latest News & Analysis
Latest News
Apollomics Reports First Half 2025 Financial Results
2 months ago
Quick Summary
Apollomics Inc. (Nasdaq: APLM) reported its financial results for H1 2025, focusing on its development of oncology drugs for difficult-to-treat cancers.
Why It Matters
Apollomics' financial results indicate its performance and potential growth in oncology, impacting investor confidence and stock valuation in a competitive biopharmaceutical market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Apollomics Announces Settlement of Cayman Litigation
3 months ago
Quick Summary
Apollomics Inc. (Nasdaq: APLM) has reached a settlement agreement with TWVC Goldlink Partners and TWVC Panglin Group, resolving ongoing litigation in the Cayman Islands.
Why It Matters
The settlement may reduce legal uncertainties for Apollomics, potentially stabilizing its stock and improving investor confidence while allowing the company to focus on growth initiatives.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Apollomics Inc. announced changes to its board of directors and committee compositions, as of November 17, 2025.
Why It Matters
Changes to Apollomics' board and committee structure can signal shifts in strategy or governance, impacting investor confidence and potential future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
4 months ago
Quick Summary
Apollomics Inc. (Nasdaq: APLM) is appealing a delisting notification from Nasdaq and has requested a hearing for review of this determination.
Why It Matters
Apollomics' appeal against Nasdaq delisting could impact its stock price and investor confidence, reflecting ongoing challenges in meeting listing requirements amid its oncology drug development efforts.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Apollomics Inc. (Nasdaq: APLM) provided an operational update on October 13, 2025. Further details on the update were not specified in the excerpt.
Why It Matters
Apollomics' operational update could impact stock performance, indicating potential changes in strategy, product pipeline, or financial health, which are vital for investor decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
11 months ago
Quick Summary
Apollomics Inc. (Nasdaq: APLM) reported its fiscal year 2024 financial results and provided updates on its oncology drug candidates aimed at difficult-to-treat cancers.
Why It Matters
Apollomics' financial results and clinical updates signal its growth potential and advancements in oncology, impacting investor confidence and stock performance in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About APLM Stock
What is Apolomics Inc.'s (APLM) stock forecast for 2026?
Analyst forecasts for Apolomics Inc. (APLM) are not currently available. The stock is trading at $19.90.
Is APLM stock a good investment in 2026?
Analyst ratings for APLM are not currently available. The stock is currently trading at $19.90. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for APLM stock?
Price predictions from Wall Street analysts for APLM are not currently available. The stock is trading at $19.90.
What is Apolomics Inc.'s business model?
Apolomics Inc. operates by innovating in the biopharmaceutical sector, specifically focusing on cell and gene therapies to treat cancer. The company generates revenue through the development of novel therapeutic solutions, particularly in immuno-oncology and oncogene targeting therapies, often collaborating with scientific institutions to enhance its research and development efforts.
What is the highest forecasted price for APLM Apolomics Inc.?
Price targets from Wall Street analysts for APLM are not currently available. The stock is trading at $19.90.
What is the lowest forecasted price for APLM Apolomics Inc.?
Price targets from Wall Street analysts for APLM are not currently available. The stock is trading at $19.90.
What is the overall APLM consensus from analysts for Apolomics Inc.?
Analyst ratings for APLM are not currently available. The stock is trading at $19.90.
How accurate are APLM stock price projections?
Stock price projections, including those for Apolomics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 14, 2026 2:08 AM UTC